

Silo Pharma (SILO) a new impressive psychedelic play

 GUEST CONTRIBUTOR ·  JULY 14, 2021 ·  STOCKS

Under the radar, low float with patented psilocybin treatments comes Silo Pharma (SILO) and heads are turning with names like Pfizer (PFE), Eli Lilly (LLY) and GlaxoSmithKline (GSK) entering this space. Expect some M&A within this sector soon. Patented tech is key.

Science and commerce are looking at psychedelic substances such as psilocybin, LSD, Ketamine and MDMA and to treat many of the same neurological disorders that cannabis does and so much more.

Silo's goal is to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.

Opportunities to invest in companies developing new technologies usually come too late. They come to our attention after a significant catalyst has already moved the price significantly higher and we find ourselves wishing we'd have gotten in while the shares were cheap. SILO is a company with shares that are still affordable, and we've laid out the reasons that might change soon below.

SILO has assembled a team of scientific advisors to ensure they are looking at viable projects and they have the available capital to finance them through the full term of development.

It wasn't that long ago that developing biopharma treatments with cannabis derivatives was theoretical, and start-ups were cheap to invest in. A lot of fortunes have been made in the cannabis sector since.

Merging traditional therapeutics with psychedelic research.

Here's what's new at SILO Pharma:

On July 7, 2021, [SILO announced they extended their agreement](#) with for experimental Rheumatoid Arthritis nanoparticle homing peptide. Eric Weisblum, Chairman and CEO of Silo Pharma stated, "The ability to deliver traditional therapeutics, psilocybin or other psychedelic drugs directly to targeted areas of the body with this technology could be revolutionary by increasing the efficacy of the treatment while reducing toxicity and the amount of medication needed."

SILO has [entered into a Scientific Research Agreement](#) (SRA) with the University of California San Francisco (UCSF). This SRA, just negotiated in June 2021, will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson's, Bipolar disorder, and chronic back pain.

On October 19, 2020, SILO was approved for trading on the OTCQB Venture Market, an upgrade from the pink sheets. On May 25, 2021, [the company announced that it has submitted its initial application to list on the NASDAQ Capital Market.](#)

Also in May 2021, [the company announced](#) that its investigator led study using Psilocybin to treat Parkinson's disease has been submitted for ethics board review in the Netherlands. Eric Weisblum, CEO of Silo Pharma stated, "We are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders."

Let's look at the programs that SILO is involved with:

Investigator Lead sponsored study with Maastricht University, which utilizes repeated low doses of LSD and Psilocybin effects on cognitive and emotional dysfunction in Parkinson's disease and to understand its mechanism of action. The investigator is completing acquiring the substances for the study and will then finalize the documentation to submit to the Ethics committee.

Silo Pharma, Inc. enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis.

“Joint-homing peptides for use in the investigation and treatment of arthritogenic processes” novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis.

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS. An innovative Central nervous system-homing peptides for treatment of multiple sclerosis and other neuroinflammatory pathology, signing a Master License Agreement with the University of Maryland Baltimore.

Silo Pharma Entered into a Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Silo Pharma receives \$1M in up front licensing deal for its Psilocybin cancer therapeutic applications. In consideration for granting the license, Silo Pharma received a one-time cash payment of \$500,000 and shares of newly designated Convertible Preferred Stock valued at \$500,000 on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) if the licensed property is commercially developed.

Silo Pharma entered, completes, and grants a sub license agreement for the treatment of pain from neuroinflammation in cancer patients.

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into [Joint Venture Agreement](#) to focus on the development of ketamine using ZTI's Z-pod™ technology for the transdermal time released delivery of therapeutics.

With a current market value under \$25M, SILO looks to be under the radar of a lot of biopharma investors. With an uplist to the NASDAQ pending SILO could quickly become well known and of course the market value could soar. A cursory look at development stage biopharma NASDAQ stocks will result in a plethora of companies valued in the hundreds of millions of dollars.

SILO already has collaborations with universities to develop leading edge science and innovative therapies for some of the hardest to treat indications. The combination of psychedelic compounds with existing and newly developed therapies is a novel approach to new treatments and SILO is at the forefront of these developments.

Let's look at the SILO Intellectual Property portfolio:

U.S. Provisional Patent Application No. 63/060,573, titled "Central Nervous System Delivery of Psilocybin," filed August 3, 2020.

U.S. Provisional Patent Application No. 63/060,569, titled "Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin," filed August 3, 2020.

U.S. Provisional Patent Application No. 63/060,577, titled "Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin," filed August 3, 2020.

U.S. Provisional Patent Application No. 63/24,827, titled "Use of Psilocybin in Cancer Treatment," filed December 13, 2020.

The psychedelics sector is growing rapidly with many public companies already established and IPOs for others already planned. SILO happens to be several steps ahead of the pack with several patents pending, university collaborations and capital available for development. Its important to note that SILO is looking beyond depressive disorders and working to develop treatments for other indications.

Author and PhD, Joshua Cohen published an article on July 5, 2021, in Forbes titled ["Psychedelic Drugs Are Moving from The Fringes of Medicine to the Mainstream"](#). His insights into the sector are invaluable and he discusses the FDA relationship with psychedelic compounds. It's a great read for anyone with a current interest in this field of medicine.

SILO appears to be a value compared to its peers in the psychedelic sector (development stage, absent revenue):

Seelos Therapeutics, Inc. (SEEL) Market value – \$270M

Mind Medicine Inc. (MNMD) Market value – \$805M

COMPASS Pathways plc (CMPS) Market value – \$1.5B

Silo Pharma, Inc. (SILO) Market value – \$21M

Silo Pharma Inc's CEO and Founder, Eric Weisblum, has over 25 years of Wall Street

experience most recently in the biotechnology sector. Eric served on the board of directors of Aikido Pharma (AIKI), a Nasdaq-listed biotech company focused on the commercialization of oncology therapeutics where he advised on the operations and licensing of their technology. Prior to Aikido, he was the President of Sableridge Capital.

This article was written by [u/SituationLive4406](#)

PREVIOUS

NEXT

[AUTHORS & STAFF](#)

[PUBLISHING GUIDELINES](#)

[ADVERTISING & INVESTOR RELATIONS MARKETING](#)

[PRIVACY POLICY](#)

[ABOUT/CONTACT](#)

[FULL DISCLAIMER](#)

Copyright © 2021 Woodland Report > *for advertising & other inquiries contact editor@woodlandreport.com*